100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 100010 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100020 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Detail) 2 link:presentationLink link:calculationLink link:definitionLink 100030 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100040 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100050 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 995455 - Disclosure - Nature of Business link:presentationLink link:calculationLink link:definitionLink 995465 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 995475 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995485 - Disclosure - Collaborative Research and License Agreements link:presentationLink link:calculationLink link:definitionLink 995495 - Disclosure - Net Loss per Share Attributable to Common Stockholders link:presentationLink link:calculationLink link:definitionLink 995505 - Disclosure - Significant Agreements link:presentationLink link:calculationLink link:definitionLink 995515 - Disclosure - Other Receivables link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 995535 - Disclosure - Prepaid Expenses and Other Current Assets link:presentationLink link:calculationLink link:definitionLink 995545 - Disclosure - Accrued Expenses and Other Current Liabilities link:presentationLink link:calculationLink link:definitionLink 995555 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 995565 - Disclosure - Loan Payable link:presentationLink link:calculationLink link:definitionLink 995575 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 995585 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 995595 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 995605 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables) link:presentationLink link:calculationLink link:definitionLink 995615 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 995625 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 995635 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 995645 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 995655 - Disclosure - Loan Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 995665 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 995675 - Disclosure - Nature of Business - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995685 - Disclosure - Basis of Presentation (Additional Information) (Details) link:presentationLink link:calculationLink link:definitionLink 995695 - Disclosure - Collaborative Research and License Agreements - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995705 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Detail) link:presentationLink link:calculationLink link:definitionLink 995715 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Potential Dilutive Securities Excluded from Computation of Diluted Net Loss per Common Share (Detail) link:presentationLink link:calculationLink link:definitionLink 995725 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995735 - Disclosure - Significant Agreements - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995745 - Disclosure - Other Receivables (Additional Information) (Details) link:presentationLink link:calculationLink link:definitionLink 995755 - Disclosure - Fair Value Measurements - Schedule of Fair Values of Financial Assets and Liabilities Measured at Fair Value (Detail) link:presentationLink link:calculationLink link:definitionLink 995765 - Disclosure - Fair Value Measurements - Summary of Fair Value (Detail) link:presentationLink link:calculationLink link:definitionLink 995775 - Disclosure - Fair Value Measurements - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995785 - Disclosure - Fair Value Measurements - Summary of Available-for-Sale Securities (Detail) link:presentationLink link:calculationLink link:definitionLink 995795 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Detail) link:presentationLink link:calculationLink link:definitionLink 995805 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Detail) link:presentationLink link:calculationLink link:definitionLink 995815 - Disclosure - Stock-Based Compensation - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995825 - Disclosure - Stock-Based Compensation - Share Based Compensation Expense Related to Issuance of Stock Option Awards to Employees and Non Employees Related to Employee Stock Purchase Plan (Detail) link:presentationLink link:calculationLink link:definitionLink 995835 - Disclosure - Stock-Based Compensation - Compensation Expense by Type of Award (Detail) link:presentationLink link:calculationLink link:definitionLink 995845 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Units Activity (Detail) link:presentationLink link:calculationLink link:definitionLink 995855 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Units Activity (Detail) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 995865 - Disclosure - Loan Payable - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995875 - Disclosure - Stockholders' Equity - Summary of Changes in Stockholders' Equity (Detail) link:presentationLink link:calculationLink link:definitionLink 995885 - Disclosure - Stockholders' Equity - Summary of Changes in Stockholders' Equity (Parenthetical) (Detail) link:presentationLink link:calculationLink link:definitionLink 995895 - Disclosure - Stockholders' Equity - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995905 - Disclosure - Stockholders' Equity - Schedule of Common Stock Reserved for Future Issuance (Detail) link:presentationLink link:calculationLink link:definitionLink 995915 - Disclosure - Commitments and Contingencies (Additional Information) (Details) link:presentationLink link:calculationLink link:definitionLink Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative Document Transition Report Document Transition Report Clinical trial. Clinical Trial [Member] Clinical Trial [Member] Class of warrant or right issued. Class Of Warrant Or Right Issued Warrant issued Geographical [Axis] Geographical Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Summary of Fair Value Debt Securities, Available-for-Sale Fair Value Debt Securities, Available-for-Sale, Total Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other assets Restricted Stock Units (RSUs) [Member] Non-Vested Restricted Stock Units (RSUs) [Member] Restricted Stock Units [Member] Fair Value, Inputs, Level 1 [Member] Quoted Prices (Unadjusted) in Active Markets Level 1 [Member] Revenue from Contract with Customer, Excluding Assessed Tax Total revenues Total revenues Significant Risks and Uncertainties Significant Risks And Uncertainties Policy [Text Block] Disclosure of accounting policy for Significant risks and uncertainties. Additional default interest rate. Additional Default Interest Rate Default interest rate Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Unrecognized compensation expense related to stock option and RSUs Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total Offering price Offering Price Per Share Offering price per share. Title of Individual [Domain] Title of Individual Upfront payments to be returned upon termination of agreement. Upfront Payments To Be Returned Upon Termination Of Agreement Upfront payments returned upon termination of agreement Research and Development [Abstract] UCB license agreement. Ucb License Agreement [Member] UCB License Agreement [Member] Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Schedule of Fair Values of Financial Assets and Liabilities Measured at Fair Value Operating Lease, Liability, Noncurrent Right-of-use liability, less current portion Schedule of Stock by Class [Table] Schedule Of Stock By Class [Table] Fair Value Measurement [Domain] Fair Value Measurement Debt Securities, Available-for-Sale [Table] Debt Securities Available For Sale [Table] Reimbursable costs. Reimbursable Costs Reimbursable costs Liabilities, Fair Value Disclosure Total liabilities Class of Stock [Line Items] Class Of Stock [Line Items] Class of Stock [Line Items] Other Receivables, Net, Current [Abstract] Assets, Current Total current assets Prepayment Fee Prepayment Fee Pre-Payment Fees Payments for Other Fees Liabilities and Equity Total liabilities and stockholders’ equity Entity Address, State or Province Entity Address, State or Province Stock Issued During Period, Value, New Issues Common stock issued at fair value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share-based compensation, stock options outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Beginning Balance Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Ending Balance Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted average grant date fair value of options Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive loss Trading Symbol Trading Symbol Common Stock, Shares, Issued Common stock, shares issued Debt Securities, Available-for-Sale [Line Items] Schedule Of Available For Sale Securities [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Weighted average grant date fair value per share Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Total prepaid expenses and other current assets Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Net Income (Loss) Attributable to Parent [Abstract] Numerator—basic and diluted: Remaining contractual obligation. Remaining Contractual Obligation Remaining contractual obligation Schedule of Long-Term Debt Instruments [Table] Debt Instrument [Table] Shares, Outstanding Beginning balance, shares Ending balance, shares Common Stock, Capital Shares Reserved for Future Issuance Shares available for issuance Percentage of prepayment premium of principal amount outstanding thereafter. Percentage Of Prepayment Premium Of Principal Amount Outstanding Thereafter Percentage of prepayment premium of principal amount outstanding thereafter prior to maturity date Accumulated Other Comprehensive(Loss) / Income [Member] AOCI Attributable to Parent [Member] Two thousand and twenty two performance awards. Two Thousand And Twenty Two Performance Awards [Member] 2022 Performance Awards [Member] Upfront payments received. Upfront Payments Received License agreement upfront payment received Reimbursable expense due from counterparty. Reimbursable Expense Due From Counterparty Reimbursable expense due from counterparty Entity Address, City or Town Entity Address, City or Town Class of Warrant or Right, Outstanding Warrants Outstanding Line of credit facility minimum cash covenant waived. Line Of Credit Facility Minimum Cash Covenant Waived Minimum cash covenant waived Debt Disclosure [Text Block] Loan Payable Number of shares, Vested and exercisable, end of the period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Additional Paid-in Capital [Member] Additional Paid-In Capital [Member] Non-US [Member] Ex-U.S. Countries [Member] Employee service share based compensation recognized stock options not met. Employee Service Share Based Compensation Recognized Stock Options Not Met Recognized compensation expense related to stock option not met Liabilities, Current [Abstract] Current liabilities: Assets, Current [Abstract] Current assets: Counterparty Name [Axis] Counterparty Name Preferred Stock, Par or Stated Value Per Share Preferred stock, par value Operating Lease, Liability, Current Current portion of right-of-use liability Lender Name [Axis] Lender Name Property, Plant and Equipment, Net Property and equipment, net Property, Plant and Equipment, Net, Total Current portion of capital lease. Current Portion Of Capital Lease Current portion of capital lease Investment Income, Interest Interest income Business Combination, Contingent Consideration, Liability, Total Business Combination, Contingent Consideration, Liability Contingent liabilities Scenario [Domain] Scenario Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative Entity Central Index Key Entity Central Index Key Class of Warrant or Right, Number of Securities Called by Warrants or Rights Warrants issued (in shares) Plan Name [Domain] Plan Name Two thousand seven and two thousand fifteen stock incentive plan. Two Thousand Seven And Two Thousand Fifteen Stock Incentive Plan [Member] 2015 and 2007 [Member] US Treasury and Government [Member] US Treasury and Federal bonds [Member] Restricted Cash, Noncurrent Restricted cash Assets, Fair Value Disclosure Total assets Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Preferred Stock, Shares Outstanding, Beginning Balance Preferred Stock, Shares Outstanding, Ending Balance Liabilities, Current Total current liabilities Entity Tax Identification Number Entity Tax Identification Number Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Stock Issued During Period, Value, Employee Stock Purchase Plan Stock purchase under ESPP Share-Based Payment Arrangement, Disclosure [Abstract] Plan Name [Axis] Plan Name Geographical [Domain] Geographical Assets Total assets Operating Lease, Right-of-Use Asset Right-of-use asset, net Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Share based compensation Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Accrued expenses and other liabilities Entity Registrant Name Entity Registrant Name Debt instrument tranche two Debt Instrument Tranche Two [Member] Tranche 2 [Member] Entity Address, Address Line Three Entity Address, Address Line Three Retained Earnings (Accumulated Deficit) Accumulated deficit Retained Earnings (Accumulated Deficit), Total Proceeds from Stock Plans Proceeds from Employee Stock Purchase Plan Capital lease, less current portion. Capital Lease Less Current Portion Capital lease, less current portion Retained Earnings [Member] Accumulated Deficit [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Number of Shares, Unvested, Ending balance Number of Shares, Unvested, Beginning balance Stock Issued During Period, Shares, Employee Stock Purchase Plans Stock purchase under ESPP, shares Minimum [Member] Minimum [Member] Proceeds from Stock Options Exercised Proceeds from stock option exercises Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Schedule of Prepaid Expenses and Other Current Assets Hercules Capital, Inc. Hercules Capital Inc [Member] Hercules [Member] Forecast [Member] Scenario Forecast [Member] Equity Component [Domain] Equity Component Stock options [Member] Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Debt Disclosure [Abstract] Net Income (Loss) Available to Common Stockholders, Diluted Net loss attributable to common stockholders - diluted Net loss attributable to common stockholders - diluted Debt Instrument, Basis Spread on Variable Rate Basis spread on variable rate Entity Current Reporting Status Entity Current Reporting Status Common Stock, Shares Authorized Common stock, shares authorized Research and Development Expense Research and development Research and development expense Research and Development Expense, Total Revenue recognized upon transfer of license agreement. Revenue Recognized Upon Transfer Of License Agreement Revenue recognized upon transfer of license agreement Share based compensation arrangement by share based payment award stock option grant date fair value. Share Based Compensation Arrangement By Share Based Payment Award Stock Option Grant Date Fair Value Options grant date fair value amount Assets [Abstract] ASSETS Proceeds from issuance of common stock in follow-on public stock offering, net Proceeds from issuance of common stock in at-the-market stock offering, net Proceeds from issuance of common stock Incyte corporation. Incyte Corporation [Member] Incyte Corporation [Member] Common stock reserved for issuance Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Prepaid conference, meeting costs Prepaid Conference, Meeting Costs Prepaid conference, meeting costs Interest Receivable, Current Interest receivable on investments Common stock, $0.0001 par value, 200,000,000 shares authorized; 84,979,686 and 84,826,632 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively Common Stock, Value, Issued Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Accrued Expenses and Other Current Liabilities Upfront payments. Upfront Payments Upfront milestone payable Current Fiscal Year End Date Current Fiscal Year End Date Share-Based Payment Arrangement, Noncash Expense Stock-based compensation Share-Based Payment Arrangement, Noncash Expense, Total Operating Income (Loss) Loss from operations Debt Securities, Available-for-Sale, Realized Gain (Loss) Realized gains or losses recognized on the sale or maturity of available-for-sale securities Debt Securities, Available-for-Sale, Realized Gain (Loss), Total Accrued Research And Development Costs Accrued Research And Development Costs Accrued research and development costs Research and Development Expense [Member] Research and Development [Member] Nature of Operations [Text Block] Nature of Business Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale Proceeds from sales and maturities of short-term investments Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale, Total Stock issued during period value at the market offering net. Stock Issued During Period Value At The Market Offering Net Proceeds from ATM sales Significant agreements disclosure. Significant Agreements Disclosure [Text Block] Significant Agreements Share-Based Payment Arrangement, Expense Share based compensation expense, total Refundable fee payble Refundable Fee Payble Refundable Fee Payble Accumulated other comprehensive (loss) gain AOCI, Debt Securities, Available-for-Sale, Adjustment, after Tax Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures Stock option granted to certain executives, consultants and employees Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures, Total Other Comprehensive Income (Loss), Net of Tax [Abstract] Other comprehensive loss: Employees. Employees [Member] Employees [Member] Federal bonds. Federal Bonds [Member] Federal Bonds [Member] Depreciation and related adjustment. Depreciation And Related Adjustment Depreciation Measurement Basis [Axis] Measurement Basis Other Nonoperating Income (Expense) Other Nonoperating Income (Expense), Total Other expense Payment on term loan Prepayment of loan Payments for (Proceeds from) Deposit on Loan Number Of Pre Funded Warrants Exercised For Common Stock Number Of Pre Funded Warrants Exercised For Common Stock Number of pre funded warrants exercised for common stock Operating Expenses [Abstract] Operating expenses: Proceeds from License Fees Received License fees Debt Securities, Available-for-Sale [Table Text Block] Summary of Available-for-Sale Securities Prepaid State and Local Taxes Prepaid State and Local Taxes Prepaid state and local taxes Commitments and Contingencies Disclosure [Abstract] Other Assets, Noncurrent Other assets Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Share-based compensation, stock options granted Other Accrued Liabilities, Current Other Equity [Text Block] Stockholders' Equity Stock issued during period shares at the market offering net. Stock Issued During Period Shares At The Market Offering Net Proceeds from ATM sales, shares Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Earnings Per Share Basic [Line Items] Other receivable Other receivable Increase (Decrease) in Accounts Receivable and Other Operating Assets Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Unrealized Gains Weighted Average Grant Date Fair Value, Vested and exercisable, end of the period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Equity, Attributable to Parent [Abstract] Stockholders’ equity: Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Entity [Domain] Entity Line of Credit Facility, Maximum Borrowing Capacity Aggregate maximum borrowings Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Schedule of Common Stock Reserved for Future Issuance Earnings Per Share [Abstract] Accounting Policies [Abstract] Cowen and Company LLC. Cowen And Company L L C [Member] Cowen and Company LLC [Member] Prepaid Subscriptions Prepaid Subscriptions Prepaid subscriptions Scenario [Axis] Scenario Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Earnings Per Share, Basic Net loss per share attributable to common stockholders—basic Net loss per share attributable to common stockholders—basic Earnings Per Share, Basic, Total Commitments and Contingencies Commitments and contingencies (Note 12) Income Statement [Abstract] Commercial Paper, Not Included with Cash and Cash Equivalents [Member] Commercial Paper [Member] Two thousand and nineteen performance awards. Two Thousand And Nineteen Performance Awards [Member] 2019 Performance Awards [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Share-based compensation, stock options vested Statistical Measurement [Domain] Statistical Measurement Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Document Period End Date Document Period End Date Statistical Measurement [Axis] Statistical Measurement Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Accrued milestone costs Accrued milestone costs Accrued Milestone Costs Earnings Per Share, Diluted Net loss per share attributable to common stockholders—diluted Net loss per share attributable to common stockholders— diluted Earnings Per Share, Diluted, Total Gross proceeds from offering Gross Proceeds From Offering Gross proceeds from offering. Debt Instrument, Name [Domain] Debt Instrument, Name Payment for fully-refundable fee Payment for Fully-refundable Fee Payment for Fully-refundable Fee Derivative Liability Derivative liability Derivative Liability, Total Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV Related Party Transaction [Domain] Related Party Transaction Milestone Expenses Paid Milestone Expenses Paid Additional Paid in Capital, Common Stock Additional paid-in capital Schedule of Maturities of Long-Term Debt [Table Text Block] Summary of Maturities of Principal Obligations Under Long-term Debt US Treasury Securities [Member] U.S. Treasury [Member] Number of shares, Exercised/Released Stock options exercised, shares Number of shares, Exercised/Released Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Proceeds from exercise of stock options, shares Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS’ EQUITY Percentage of end of term charge to future draws. Percentage Of End Of Term Charge To Future Draws Percentage of end of term charge to future draws Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table] Schedule Of Earnings Per Share Basic By Common Class [Table] Exercise Of Prefunded Warrants, Shares Exercise of prefunded warrants shares. Prefunded warrants, exercise, shares Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Interactive Data Current Entity Interactive Data Current Private Placement [Member] Private Placement [Member] Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accounts Payable, Total Revenue, Product and Service [Extensible Enumeration] Type of revenue [extensible list] Credit Facility [Domain] Credit Facility Equity [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Number of Shares, Granted Weighted Average Grant Date Fair Value, Exercised/Released Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code State of incorporation Equity Components [Axis] Equity Components Term loan. Term Loan [Member] Term Loan [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Weighted Average Grant Date Fair Value, Vested Local Phone Number Local Phone Number Sale of Stock [Axis] Sale of Stock Statement of Cash Flows [Abstract] Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block] Fair Value Measurements Organization, Consolidation and Presentation of Financial Statements [Abstract] Common Stock, Par or Stated Value Per Share Common stock, par value License agreements expiration period. License Agreements Expiration Period License expiration year Vesting of Restricted Stock Units, Shares Vesting of Restricted Stock Units, Shares Vesting of RSU, shares Debt Instrument, Interest Rate, Stated Percentage Interest rate Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Weighted average period to recognize compensation expense Collaboration payable, net Collaboration Payable, Current Collaboration Payable, Current Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Maximum [Member] Maximum [Member] Collaboration receivable Collaboration receivable Collaboration receivable, net Collaboration receivable Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights Vesting period, description Dividends Deemed dividend due to warrant reset Dividends, Total Related Party Transaction [Axis] Related Party Transaction Scenario two. Scenario Two [Member] Available through November 30, 2022 [Member] Fair Value, Inputs, Level 3 [Member] Significant Unobservable Inputs Level 3 [Member] APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Stock-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total Fair Value, Recurring and Nonrecurring [Table] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Research and Development Arrangement, Contract to Perform for Others [Line Items] Research And Development Arrangement Contract To Perform For Others [Line Items] NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Debt instrument, tranche three. Debt Instrument Tranche Three [Member] Tranche 3 [Member] Payables and Accruals [Abstract] Milestone payment due. Milestone Payment Due Milestone payment payable First amendment to loan and security agreement. First Amendment To Loan And Security Agreement [Member] First Amendment to Loan Agreement [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Share-based compensation, stock options cancelled License agreement. License Agreement [Member] License Agreement [Member] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Potential Dilutive Securities Excluded from Computation of Diluted Net Loss per Common Share Liability related to letter agreement. Liability Related To Letter Agreement Liability related to letter agreement City Area Code City Area Code Net Cash Provided by (Used in) Operating Activities [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Selling, general and administrative General and Administrative Expense General and Administrative Expense, Total Selling, General and Administrative [Member] Selling, General and Administrative Expenses [Member] Weighted Average Number of Shares Outstanding, Basic Weighted-average number of common shares used to compute net loss per share attributable to common stockholders —basic Weighted-average number of common shares used to compute net loss per share attributable to common stockholders—basic Weighted Average Number of Shares Outstanding, Basic, Total Collaboration expense due to counterparty. Collaboration Expense Due To Counterparty Collaboration expense due to counterparty Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value Fair value of restricted stock units vested Development costs associated with clinical trials. Development Costs Associated With Clinical Trials Development costs associated with clinical trials Net Cash Provided by (Used in) Financing Activities [Abstract] CASH FLOWS FROM FINANCING ACTIVITIES: Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Summary of Restricted Stock Units Activity Statement [Table] Statement [Table] Document Fiscal Period Focus Document Fiscal Period Focus Liabilities, Noncurrent Total long-term liabilities Accrued Professional Fees, Current Accrued professional fees Statement [Line Items] Statement [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Anti-dilutive securities excluded from computation of diluted net loss per common share Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Ending Balance 6/30/22 Beginning Balance 12/31/21 Warrant [Member] Warrant [Member] Asset Class [Domain] Asset Class Common Stock [Member] Common Stock [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Employee stock purchase plan. Employee Stock Purchase Plan [Member] Employee Stock Purchase Plan [Member] Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value, Total Contractual obligations term. Contractual Obligations Term Period of contractual obligation Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Share Based Compensation Expense Related to Issuance of Stock Option Awards to Employees and Non Employees Related to Employee Stock Purchase Plan Other receivable Other Assets, Current Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Change In Fair Value Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Change In Fair Value Change in fair value Change in fair value Accretion (Amortization) of Discounts and Premiums, Investments Accretion of investments Summary in Compensation Expense by Type of Award Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Line of credit facility minimum cash covenant. Line Of Credit Facility Minimum Cash Covenant Minimum cash covenant Antidilutive Securities, Name [Domain] Antidilutive Securities, Name Deposits Assets, Current Short-term deposits Cover [Abstract] Document Fiscal Year Focus Document Fiscal Year Focus Sale of Stock [Domain] Sale of Stock Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted Average Grant Date Fair Value, Granted Potential milestone payments upon achievement of milestone. Potential Milestone Payments Upon Achievement Of Milestone Potential milestone payments to be made Scenario Three. Scenario Three [Member] Not to Draw First from Tranche 2 [Member] Security Exchange Name Security Exchange Name Long-Term Investments, Total Long-Term Investments Long-term investments New Accounting Pronouncements, Policy [Policy Text Block] Recently Issued and Adopted Accounting Pronouncements Preferred Stock, Shares Authorized Preferred stock, shares authorized Legal Entity [Axis] Legal Entity Weighted Average Number of Shares Outstanding, Diluted [Abstract] Denominator—basic and diluted: Development and regulaotry milestones Expenses Development and regulaotry milestones Expenses Stock Issued During Period, Value, Stock Options Exercised Proceeds from exercise of stock options Entity Emerging Growth Company Entity Emerging Growth Company Amendment Flag Amendment Flag Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Unrealized Losses Percentage of prepayment premium of principal amount outstanding in second year. Percentage Of Prepayment Premium Of Principal Amount Outstanding In Second Year Percentage of prepayment premium of principal amount outstanding in second year Basis of Accounting, Policy [Policy Text Block] Significant Accounting Policies Other Current Assets [Text Block] Prepaid Expenses and Other Current Assets Two thousand fifteen omnibus incentive plan. Two Thousand Fifteen Omnibus Incentive Plan [Member] 2015 Plan [Member] UCB Biopharma. U C B Biopharma [Member] UCB Biopharma [Member] Variable Rate [Domain] Variable Rate Securities Act File Number Entity File Number Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Upfront license fees paid. Upfront License Fees Paid Up-front license fee paid Vitae Pharmaceuticals, Inc. Vitae Pharmaceuticals Inc [Member] Vitae Pharmaceuticals Inc [Member] Incyte collaboration agreement and share purchase agreement. Incyte Collaboration Agreement And Share Purchase Agreement [Member] Incyte Collaboration Agreement and Share Purchase Agreement [Member] Number of pre-funded warrants exchanged for common stock. Number Of Pre Funded Warrants Exchanged For Common Stock Pre-funded warrants exchange Unrealized (loss) gain on short-term investments OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Unrealized gains on short-term investments Share-Based Payment Arrangement [Abstract] Bayer Pharma AG . Bayer Pharma Ag [Member] Bayer Pharma AG [Member] Non-cash operating lease expense. Noncash Operating Lease Expense Non-cash operating lease expense At the market stock offering. At The Market Stock Offering [Member] At-the-Market Offering [Member] Accounts Payable, Current Accounts payable Accounts Payable, Current, Total Debt Instrument [Axis] Debt Instrument Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Weighted Average Grant Date Fair Value, Unvested, Beginning balance Weighted Average Grant Date Fair Value, Unvested, Beginning balance Weighted Average Grant Date Fair Value, Unvested, Ending Balance Operating Expenses Total operating expenses Accrued clinical costs current. Accrued Clinical Costs Current Accrued clinical study and trial costs Accrued Liabilities and Other Liabilities Accrued expenses and other current liabilities Total accrued expenses and other current liabilities Entity Address, Address Line Two Entity Address, Address Line Two Preferred stock, $0.001 par value, 10,000,000 shares authorized; 0 shares outstanding at March 31, 2024 and December 31, 2023 Preferred Stock, Value, Issued Entity Small Business Entity Small Business Entity Shell Company Entity Shell Company Number of Operating Segments Number of operating segments Title of Individual [Axis] Title of Individual Two thousand and seven stock incentive plan. Two Thousand And Seven Stock Incentive Plan [Member] 2007 Plan [Member] Liabilities, Noncurrent [Abstract] Long-term liabilities: Earnings Per Share [Text Block] Net Loss per Share Attributable to Common Stockholders End-of Term fees Payment for end-of term fees Payment for end-of term fees Revenues [Abstract] Revenue: Allergan license agreement. Allergan License Agreement [Member] Allergan License Agreement Member Entity Address, Address Line One Entity Address, Address Line One Cash and Cash Equivalents, Fair Value Disclosure Cash and cash equivalents Contractual Obligation Aggregate payment obligation Contractual Obligation, Total Antidilutive Securities [Axis] Antidilutive Securities Collaboration receivable, net Increase Decrease In Collaboration Receivable Increase decrease in collaboration receivable. Accrued contractual obligation. Accrued Contractual Obligation Accrued contractual obligation Prepaid rent Prepaid Rent Loan and security agreement. Loan And Security Agreement [Member] Loan Agreement [Member] Income Statement Location [Axis] Income Statement Location Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total Number of pre funded warrants cashless exchanged for common stock. Number Of Pre Funded Warrants Cashless Exchanged For Common Stock Pre-funded warrants cashless exchange Prepaid Insurance Prepaid insurance Line of Credit Facility, Lender [Domain] Line of Credit Facility, Lender Other Receivables Other Receivables [Text Block] Other Receivables [Text Block] Fair Value, Inputs, Level 2 [Member] Significant Other Observable Inputs Level 2 [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Prefunded warrants, exercise Adjustment of Warrants Granted for Services Title of 12(b) Security Title of 12(b) Security Percentage of prepayment premium of principal amount outstanding in first year. Percentage Of Prepayment Premium Of Principal Amount Outstanding In First Year Percentage of prepayment premium of principal amount outstanding in first year 2023 Inducement Plan [Member] Two Thousand Twenty Three Inducement Incentive Plan [Member] Two Thousand Twenty Three Inducement Incentive Plan [Member] Pre funded warrants. Pre Funded Warrants [Member] Pre Funded Warrants [Member] Fair Value Measurements [Table] Fair Value Measurements [Table] Fair Value Measurements [Table] Stock issued during period value at the market offering expenses. Stock Issued During Period Value At The Market Offering Expenses ATM Offering, offering cost Prime Rate [Member] Wall Street Journal Prime Rate [Member] Derivative Liability [Abstract] Derivative Liability: Scenario one. Scenario One [Member] Available through April 30, 2022 [Member] Aggregate potential milestone payable. Aggregate Potential Milestone Payable Aggregate potential milestone payable Global and united states. Global And United States [Member] Global and U.S. [Member] Net Cash Provided by (Used in) Investing Activities [Abstract] CASH FLOWS FROM INVESTING ACTIVITIES: Reported Value Measurement [Member] Carrying Value [Member] Portion at Fair Value Measurement [Member] [Default] Portion at Fair Value Measurement [Member] Warrants to purchase common stock. Warrants To Purchase Common Stock [Member] Warrants to Purchase Common Stock [Member] Interest Expense, Debt Interest expense related to the loan agreement Interest Expense, Debt, Total Increase decrease in contractual obligation. Increase Decrease In Contractual Obligation Increase in contractual obligation Warrant, Down Round Feature, Decrease in Net Income to Common Shareholder, Amount Deemed dividend due to warrant reset Non-Refundable Cash Payments [Member] Non Refundable Cash Payments [Member] Non refundable cash payments. Common Stock, Shares, Outstanding Common stock, shares outstanding Common Stock, Shares, Outstanding, Beginning Balance Common Stock, Shares, Outstanding, Ending Balance Share-Based Payment Arrangement [Text Block] Stock-Based Compensation Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Weighted Average Grant Date Fair Value, Forfeited At the market equity offering sales agreement. At The Market Equity Offering Sales Agreement [Member] At The Market Equity Offering Sales Agreement [Member] Income Statement Location [Domain] Income Statement Location Document Type Document Type Other Prepaid Expense, Current Other Line of Credit Facility, Interest Rate Description Interest rate description Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Collaboration and license agreement allocated consideration received to derivative liability. Collaboration And License Agreement Allocated Consideration Received To Derivative Liability Allocated consideration received to derivative liability Document Quarterly Report Document Quarterly Report Counterparty Name [Domain] Counterparty Name Net Income (Loss) Available to Common Stockholders, Basic Net loss attributable to common stockholders - basic Net loss attributable to common stockholders Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Share-based compensation, stock options net of cancellations Number of Shares, Forfeited Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Entity Filer Category Entity Filer Category Fair value measurements. Fair Value Measurements [Line Items] Fair Value Measurements [Line Items] Schedule of Stockholders Equity [Table Text Block] Summary of Changes in Stockholders' Equity Eastern Cooperative Oncology Group. Eastern Cooperative Oncology Group [Member] Eastern Cooperative Oncology Group [Member] Variable Rate [Axis] Variable Rate Short-Term Investments Short-term investments Short-Term Investments, Total Asset Class [Axis] Asset Class Total other income, net Nonoperating Income (Expense) Liabilities Total liabilities Payments to Acquire Short-Term Investments Purchases of short and long-term investments Equity, Attributable to Parent Ending balance Beginning balance Total stockholders’ equity Collaboration and license agreement. Collaboration And License Agreement [Member] Incyte Agreement [Member] Net loss Nonoperating Income (Expense) [Abstract] Other income (expense), net: Interest Expense Interest expense Interest Expense, Total Business Description and Basis of Presentation [Text Block] Basis of Presentation Schedule of Research and Development Arrangement, Contract to Perform for Others [Table] Schedule Of Research And Development Arrangement Contract To Perform For Others [Table] Commercialization milestones and tiered royalties. Commercialization Milestones And Tiered Royalties Commercialization milestones and tiered royalties Adjustment to additional paid in capital employee withholdings employee stock purchase plan. Adjustment To Additional Paid In Capital Employee Withholdings Employee Stock Purchase Plan Employee withholdings ESPP Corporate Debt Securities [Member] Corporate Bonds [Member] Statement of Financial Position [Abstract] Collaborative research and license agreements. Collaborative Research And License Agreements [Text Block] Collaborative Research and License Agreements Weighted Average Number of Shares Outstanding, Diluted Weighted-average number of common shares used to compute net loss per share attributable to common stockholders—diluted Weighted-average number of common shares used to compute net loss per share attributable to common stockholders—diluted Weighted Average Number of Shares Outstanding, Diluted, Total Credit Facility [Axis] Credit Facility Shares Issued, Price Per Share Purchase price per share Available For Sale Securities Fair Value Disclosure [Abstract] Available For Sale Securities Fair Value Disclosure [Abstract] Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Schedule of Accrued Expenses and Other Current Liabilities Debt Securities, Available-for-Sale, Amortized Cost Amortized Cost Use of Estimates, Policy [Policy Text Block] Use of Estimates Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Series Warrants [Member] Series Warrants [Member] Series warrants. Fair Value Disclosures [Abstract] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV Collaboration receivable (payable), net Increase Decrease In Collaboration Receivable/Payable Increase Decrease In Collaboration Receivable/Payable Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Number of Shares, Vested Stock Issued During Period, Shares, New Issues Common stock shares purchased Common stock, new shares issued Employee-related Liabilities, Current Accrued compensation and related costs Employee-related Liabilities, Current, Total Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations CASH, CASH EQUIVALENTS AND RESTRICTED CASH —end of period CASH, CASH EQUIVALENTS AND RESTRICTED CASH—beginning of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total